{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:03:24Z","timestamp":1762866204341},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,6,23]],"date-time":"2013-06-23T00:00:00Z","timestamp":1371945600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s00277-013-1816-z","type":"journal-article","created":{"date-parts":[[2013,6,22]],"date-time":"2013-06-22T06:53:32Z","timestamp":1371884012000},"page":"1625-1632","source":"Crossref","is-referenced-by-count":7,"title":["Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy"],"prefix":"10.1007","volume":"92","author":[{"given":"Huafeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yungui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,23]]},"reference":[{"key":"1816_CR1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330\u20131340","journal-title":"N Engl J Med"},{"key":"1816_CR2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/JBM.S13067","volume":"3","author":"PP Piccaluga","year":"2012","unstructured":"Piccaluga PP, Paolini S, Bertuzzi C, De Leo A, Rosti G (2012) First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation. J Blood Med 3:151\u2013156","journal-title":"J Blood Med"},{"key":"1816_CR3","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE, Jones D, O\u2019Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H (2010) Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 28:392\u2013397","journal-title":"J Clin Oncol"},{"key":"1816_CR4","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/blood-2002-07-2053","volume":"101","author":"T Bumm","year":"2003","unstructured":"Bumm T, M\u00fcller C, Al-Ali HK, Krohn K, Shepherd P, Schmidt E, Leiblein S, Franke C, Hennig E, Friedrich T, Krahl R, Niederwieser D, Deininger MW (2003) Emergence of clonal cytogenetic abnormalities in Ph\u2212 cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 101:1941\u20131949","journal-title":"Blood"},{"key":"1816_CR5","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/cncr.22936","volume":"110","author":"MW Deininger","year":"2007","unstructured":"Deininger MW, Cortes J, Puette R, Park B, Hochhaus A, Baccarani M, Stone R, Fischer T, Kantarjianaq H, Niederwieser D, Gambacorti-Passerini C, So C, Gathmann I, Goldman JM, Smith D, Druker BJ, Guilhot F (2007) The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 110:1509\u20131519","journal-title":"Cancer"},{"key":"1816_CR6","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3324\/haematol.11064","volume":"92","author":"A Fabarius","year":"2007","unstructured":"Fabarius A, Haferlach C, M\u00fcller MC, Erben P, Lahaye T, Giehl M, Frank O, Seifarth W, Hehlmann R, Hochhaus A (2007) Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica 92:834\u2013837","journal-title":"Haematologica"},{"issue":"8","key":"1816_CR7","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1182\/blood-2007-05-092437","volume":"110","author":"VA Melo De","year":"2007","unstructured":"De Melo VA, Milojkovic D, Khorashad JS, Marin D, Goldman JM, Apperley JF, Reid AG (2007) Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia. Blood 110(8):3086\u20133087","journal-title":"Blood"},{"key":"1816_CR8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cancergencyto.2006.12.011","volume":"176","author":"A Zeidan","year":"2007","unstructured":"Zeidan A, Kakati S, Anderson B, Barcos M, Wetzler M (2007) Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case. Cancer Genet Cytogenet 176:169\u2013171","journal-title":"Cancer Genet Cytogenet"},{"key":"1816_CR9","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.leukres.2009.05.010","volume":"33","author":"C Baldazzi","year":"2009","unstructured":"Baldazzi C, Luatti S, Marzocchi G, Stacchini M, Gamberini C, Castagnetti F, Palandri F, Rosti G, Baccarani M, Testoni N (2009) Emergence of clonal chromosomal abnormalities in Philadelphia-negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy. Leuk Res 33:218\u2013220","journal-title":"Leuk Res"},{"issue":"1","key":"1816_CR10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1586\/17474086.1.1.29","volume":"1","author":"TD Kim","year":"2008","unstructured":"Kim TD, D\u00f6rken B, le Coutre P (2008) Nilotinib for the treatment of chronic myeloid leukemia. Expert Rev Hematol 1(1):29\u201339","journal-title":"Expert Rev Hematol"},{"key":"1816_CR11","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","volume":"111","author":"P Coutre le","year":"2008","unstructured":"le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O\u2019Brien SG, Kuliczkowski K, Hochhaus A, Mahon FX, Saglio G, Gobbi M, Kwong YL, Baccarani M, Hughes T, Martinelli G, Radich JP, Zheng M, Shou Y, Kantarjian H (2008) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia. Blood 111:1834\u20131839","journal-title":"Blood"},{"key":"1816_CR12","unstructured":"ISCN (2005) An International System for Human Cytogenetic Nomenclature. In: Mitelman F, editor. Basel, Switzerland:S. Karger"},{"key":"1816_CR13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cancergencyto.2010.02.005","volume":"199","author":"N Larsson","year":"2010","unstructured":"Larsson N, Billstr\u00f6m R, Lilljebj\u00f6rn H, Lassen C, Richter J, Ekblom M, Fioretos T (2010) Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells. Cancer Genet Cytogenet 199:89\u201395","journal-title":"Cancer Genet Cytogenet"},{"key":"1816_CR14","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/sj.leu.2403399","volume":"18","author":"C Terre","year":"2004","unstructured":"Terre C, Eclache V, Rousselot P, Imbert M, Charrin C, Gervais C, Mozziconacci MJ, Maarek O, Mossafa H, Auger N, Dastugue N, Talmant P, Van den Akker J, Leonard C, N\u2019Guyen Khac F, Mugneret F, Vigui\u00e9 F, Lafage-Pochitaloff M, Bastie JN, Roux GL, Nicolini F, Maloisel F, Vey N, Laurent G, Recher C, Vigier M, Yacouben Y, Giraudier S, Vernant JP, Salles B, Roussi J, Castaigne S, Leymarie V, Flandrin G, Lessard M, France Intergroupe pour la Leucemie Myeloide Chronique (2004) Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 18:1340\u20131346","journal-title":"Leukemia"},{"key":"1816_CR15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0165-4608(01)00486-1","volume":"2","author":"K Paulsson","year":"2001","unstructured":"Paulsson K, Sall T, Fioretos T, Mitelman F, Johansson B (2001) The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology. Cancer Genet Cytogenet 2:160\u2013165","journal-title":"Cancer Genet Cytogenet"},{"key":"1816_CR16","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/blood-2006-04-017400","volume":"108","author":"C Kovitz","year":"2006","unstructured":"Kovitz C, Kantarjian HM, Garcia-Manero G, Abruzzo LV, Cortes J (2006) Myelodysplastic syndrome and acute leukemia after imatinib mesylate therapy for chronic myeloid leukemia. Blood 108:2811\u20132813","journal-title":"Blood"},{"key":"1816_CR17","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1080\/10428190801975543","volume":"49","author":"A Athanasiadou","year":"2008","unstructured":"Athanasiadou A, Lalayanni C, Papaioannou G, Gaitatzi M, Fassas A, Anagnostopoulos A (2008) Novel chromosomal aberration in Philadelphia-negative cells of a patient with chronic myelogenous leukemia treated with dasatinib. Leuk Lymphoma 49:1012\u20131013","journal-title":"Leuk Lymphoma"},{"key":"1816_CR18","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0301-472X(03)00176-0","volume":"31","author":"E Feldman","year":"2003","unstructured":"Feldman E, Najfeld V, Schuster M, Roboz G, Chadburn A, Silver RT (2003) The emergence of Ph\u2212, trisomy \u22128+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol 31:702\u2013707","journal-title":"Exp Hematol"},{"key":"1816_CR19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2141.2007.06678.x","volume":"138","author":"A Fabarius","year":"2007","unstructured":"Fabarius A, Giehl M, Frank O, Spiess B, Zheng C, M\u00fcller MC, Weiss C, Duesberg P, Hehlmann R, Hochhaus A, Seifarth W (2007) Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability. Br J Haematol 138:369\u2013373","journal-title":"Br J Haematol"},{"key":"1816_CR20","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/21704","volume":"399","author":"ZM Yuan","year":"1999","unstructured":"Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY, Lu H, Kharbanda S, Weichselbaum R, Kufe D (1999) p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 399:814\u2013817","journal-title":"Nature"},{"key":"1816_CR21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cancergencyto.2006.04.012","volume":"170","author":"Y Lin","year":"2006","unstructured":"Lin Y, Bruyere H, Horsman DE, Pantzar T, Barnett MJ, Hogge DE, Nevill TJ, Nantel SH, SutherlandHJ TCL, Shepherd JD, Lavoie JC, Song KW, Smith CA, Forrest DL (2006) Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. Cancer Genet Cytogenet 170:16\u201323","journal-title":"Cancer Genet Cytogenet"},{"key":"1816_CR22","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","volume":"114","author":"G Rosti","year":"2009","unstructured":"Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, Capucci A, Cedrone M, Fava C, Intermesoli T, Cambrin GR, Stagno F, Tiribelli M, Amabile M, Luatti S, Poerio A, Soverini S, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M, Working Party GIMEMACML (2009) Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 114:4933\u20134938","journal-title":"Blood"},{"key":"1816_CR23","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V118.21.454.454","volume":"118","author":"A Quintas-Cardama","year":"2011","unstructured":"Quintas-Cardama A, Kantarjian H, Luthra R, O\u2019Brien S, Jabbour E, Borthakur G, Ravandi F, Garcia-Manero G, Faderl S, Konopleva M, Wierda WG, Burton E, Cortes JE (2011) Efficacy of frontline nilotinib therapy in patients (Pts) with newly diagnosed Philadelphia chromosome (Ph)-positive chronic myeloid leukemia in early chronic phase (CML\u2013CP). Blood 118:454","journal-title":"Blood"},{"key":"1816_CR24","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1002\/cncr.27479","volume":"118","author":"R Bakalova","year":"2012","unstructured":"Bakalova R, Zhelev Z, Spasov L (2012) Nilotinib versus imatinib: molecular mechanism(s) of its better efficacy. Cancer 118:5180\u20135181","journal-title":"Cancer"},{"key":"1816_CR25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1741-7015-9-99","volume":"9","author":"AM Eiring","year":"2011","unstructured":"Eiring AM, Khorashad JS, Morley K, Deininger MW (2011) Advances in the treatment of chronic myeloid leukemia. BMC Med 9:99","journal-title":"BMC Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1816-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-013-1816-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1816-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T23:35:26Z","timestamp":1595979326000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-013-1816-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,23]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1816"],"URL":"https:\/\/doi.org\/10.1007\/s00277-013-1816-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,23]]}}}